Facebook Twitter Instagram You Tube Pinterest LinkedIn RSS Podcasts Video Library Blog
 - Northwestern Memorial Hospital - Chicago
000395.jpg

Boyd E. Metzger, MD

Endocrinology, Internal Medicine

This physician is currently not accepting new patients.Read important legal notice

Office Phone: 312-695-7970

Education and Training

Medical Education:

University of Iowa Carver College of Medicine 1959

Residency:

Michael Reese Medical Center 1963

Board Certification

Internal Medicine

Locations and Directions

675 N. St. Clair
Galter 14-100
Chicago, IL 60611 312-695-7970

Biography

Boyd Metzger, M.D. is the Tom D. Spies Professor of Metabolism and Nutrition in the Division of Endocrinology, Metabolism & Molecular Medicine at Northwestern University Feinberg School of Medicine. Dr. Metzger obtained his undergraduate education at the University of South Dakota and earned his M.D. at the State University of Iowa. He was an Intern, Medical Resident and Clinical Fellow in Metabolism at Michael Reese Hospital in Chicago and a Postdoctoral Fellow in Biological Chemistry at Washington University in St Louis. Dr. Metzger's memberships in professional organizations include: the Endocrine Society, the American Diabetes Association (ADA), the American Federation for Medical Research, the Central Society for Clinical Investigation and American Association for the Advancement of Science (Fellow).

Dr. Metzger has had a career-long interest in the impact of gestational diabetes pre existing diabetes and states of altered nutrition during pregnancy on the intrauterine, perinatal and lifelong health of offspring. He has served on the editorial board of Diabetes and of Diabetologia and has been a member of the Organizing Committee of each of the four ADA sponsored International Workshop Conferences on gestational diabetes mellitus (GDM) and Chairman and Proceedings Editor of the last two. He has published more than 200 journal articles and book chapters. Currently, he is Principal Investigator of the NICHD/NIDDK funded Hyperglycemia & Adverse Pregnancy Outcome (HAPO) study. The immediate objective of HAPO is to establish the level of maternal hyperglycemia that is associated with a clinically significant risk of adverse perinatal outcome. It is hoped that future risks for obesity and metabolic disturbances can also be established through long-term follow-up.

Disclosure

View the full disclosure of external professional relationships
top